Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Free carboplatin and its derived platinum species in the systemic circulation represent the active, non-protein-bound fraction of the chemotherapy agent carboplatin (PubChem CID 42675). Carboplatin is a second-generation platinum-based antineoplastic drug that functions by forming intra-strand and inter-strand DNA cross-links, which inhibit DNA replication and trigger apoptosis in rapidly dividing cancer cells (StatPearls, Carboplatin). While effective against various malignancies, including ovarian and lung cancers, the circulating free platinum species are also responsible for significant systemic toxicities, most notably dose-limiting myelosuppression, particularly thrombocytopenia (FDA Label, Carboplatin Injection). In the context of therapeutic intervention, these circulating species can be targeted by rescue agents or cytoprotectants, such as sodium thiosulfate, which chemically neutralize the platinum to mitigate off-target damage to healthy tissues (PubMed, PMID: 15671245). Monitoring the concentration of ultrafilterable (free) platinum is critical for optimizing therapeutic efficacy while minimizing adverse effects, often utilizing the Calvert formula based on glomerular filtration rate (Journal of Clinical Oncology, DOI: 10.1200/JCO.1989.7.11.1748). The pharmacokinetics of these species are characterized by a relatively low level of protein binding compared to cisplatin, allowing for more predictable clearance and dosing strategies.
Carboplatin acts as a prodrug that undergoes aquation to form reactive platinum species, which then covalently bind to DNA, primarily at the N7 position of guanine, to form intra-strand and inter-strand cross-links (StatPearls). When targeted by rescue agents like sodium thiosulfate, these reactive species are neutralized via nucleophilic attack, forming non-toxic complexes that are excreted renally (PubMed, PMID: 15671245).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Free carboplatin and circulating platinum species.